Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

“Under the theme “Designing Future Society for Our Lives,” the Expo will address eight key thematic areas focused on global challenges, providing an exceptional platform for PNG to showcase its trade ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers. Results from the late-stage Destiny-Gastric04 study showed that Enhertu ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

The lead prospect Callio licensed from Hummingbird targets the well-known cancer protein HER2, as Enhertu does. But unlike Enhertu, it carries more than one payload. That additional cargo is supposed ...